Published: 16. May, 2022
Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing…
- Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures.
- Primary aim is to obtain pharmacokinetic data from this age group and to demonstrate that CT001 is feasible as premedication in children undergoing a painful procedure.
- Topline results are anticipated by the end of Q3 2022
Comment from Jes Trygved, CEO of Cessatech
We are very pleased with the recruitment of the last patient in this important trial in children. We anticipate having the topline results by the end of Q3 2022. Conducting clinical studies involving children creates particular challenges and it is thanks to the support and hard work of the Cessatech team, the principal investigator, the site staff and in particular the children and parents involved, that we are able to announce today this great achievement of the last patient being dosed in the trial. We continue to work hard to get CT001 available for the treatment of acute pain in children.
